Kamada (NASDAQ:KMDA) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Kamada (NASDAQ:KMDA) in a report released on Thursday morning,Benzinga reports. The firm currently has a $11.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Kamada’s Q4 2024 earnings at $0.05 EPS, FY2025 earnings at $0.26 EPS, FY2026 earnings at $0.38 EPS, FY2027 earnings at $0.45 EPS and FY2028 earnings at $0.53 EPS.

Separately, StockNews.com lowered shares of Kamada from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 27th.

Kamada Stock Down 1.7 %

NASDAQ:KMDA traded down $0.10 on Thursday, reaching $5.76. The stock had a trading volume of 17,695 shares, compared to its average volume of 29,805. The company has a market capitalization of $331.08 million, a P/E ratio of 20.89 and a beta of 1.05. Kamada has a 1-year low of $4.60 and a 1-year high of $6.53. The stock has a fifty day moving average price of $5.47 and a 200-day moving average price of $5.46.

Kamada (NASDAQ:KMDA) last released its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. The firm had revenue of $42.47 million during the quarter, compared to analysts’ expectations of $39.70 million. Kamada had a return on equity of 6.36% and a net margin of 9.92%. Sell-side analysts predict that Kamada will post 0.26 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kamada

A number of institutional investors and hedge funds have recently made changes to their positions in KMDA. Vanguard Group Inc. increased its position in Kamada by 8.2% in the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after purchasing an additional 100,800 shares during the period. Y.D. More Investments Ltd boosted its stake in shares of Kamada by 1,956.0% in the 2nd quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company’s stock valued at $3,643,000 after purchasing an additional 690,842 shares during the last quarter. Finally, Plato Investment Management Ltd acquired a new stake in shares of Kamada during the 3rd quarter worth approximately $117,000. Institutional investors own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.